Antidote Technologies, Ltd., a London, UK and NYC-based digital health company, raised $11M in funding.
The round, which brings total funding to date up to $26M, was led by Merck Global Health Innovation Fund (GHI), with participation from existing investors Smedvig Capital and Octopus Ventures, conditional upon certain regulatory clearances being obtained, and expected be finalized later this year.
The company will use the funds to accelerate the development of new capabilities for its trial matching platform, including precision medicine and EHR-matching, as well as further global expansion.
Led by Pablo Graiver, Founder and CEO, Antidote has created Antidote Match, a clinical trial matching platform that currently reaches millions of patients in more than 180 online communities such as JDRF, Lung Cancer Alliance, and Healthline – bringing new studies to millions of patients every month. Patients answer questions about their health, and the platform provides matching studies in their neighborhood.
Antidote Match is based on generating structured eligibility criteria, proprietary algorithms, and machine learning. To date, the company has made 14,000 clinical trials matchable and plans to reach full coverage of US trials next year with enhanced capabilities, such as matching cancer patients to studies using mutation-level data. Notably, the company is already a participant in the Cancer Moonshot project.